StoxKrishna Institute of Medical Sciences vs Neuland Laboratories: share price & financials comparison
NSE: KIMS vs NEULANDLAB · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Krishna Institute of Medical Sciences vs Neuland Laboratories at a glance
Krishna Institute of Medical Sciences (KIMS) has a market capitalisation of ₹30,366 Cr, against ₹25,414 Cr for Neuland Laboratories (NEULANDLAB). Over the past year Neuland Laboratories has returned +27.9%, compared with -1.7% for Krishna Institute of Medical Sciences. On valuation, Neuland Laboratories trades at a lower P/E of 56.2 versus 143.0. Neuland Laboratories earns a higher return on equity (22.3% vs 5.4%). Krishna Institute of Medical Sciences comes out ahead on valuation and growth. Neuland Laboratories comes out ahead on size, profitability, financial health, momentum and technicals. Across the scored metrics below, Krishna Institute of Medical Sciences leads on 6 and Neuland Laboratories on 10. On StoxGud's 10-point checklist, Krishna Institute of Medical Sciences scores 4/10 and Neuland Laboratories scores 7/10.
| Metric | Krishna Institute of Medical Sciences | Neuland Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹30,366 Cr | ₹25,414 Cr |
| Revenue (latest FY) | ₹3,905 Cr | ₹2,023 Cr |
| Net profit (latest FY) | ₹241 Cr | ₹364 Cr |
| Valuation | ||
| P/E | 143.0 | 56.2 |
| P/B | 7.72 | 12.52 |
| Dividend yield | 0.68% | 0.06% |
| Profitability | ||
| Return on equity | 5.4% | 22.3% |
| Net profit margin | 4.6% | 19.6% |
| Operating margin | 19.3% | 30.6% |
| Growth | ||
| Revenue growth (YoY) | +39.9% | -12.6% |
| Net profit growth (YoY) | +11.8% | — |
| Revenue CAGR (multi-year) | +24.0% | +16.6% |
| Financial health | ||
| Debt to equity | 0.90 | 0.17 |
| Momentum | ||
| 1-month return | +4.2% | -9.0% |
| 1-year return | -1.7% | +27.9% |
| 3-year CAGR | +24.8% | +69.6% |
| 5-year CAGR | +25.3% | +64.0% |
| 10-year CAGR | — | +34.4% |
| Distance from 52W high | -15.0% | -17.9% |
| Technicals | ||
| RSI (14) | 66 | 50 |
| Price vs 200-day avg | -0.7% | +12.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Krishna Institute of Medical Sciences | Neuland Laboratories |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✓ |
| P/E below industry median | ✗ | ✗ |
| Score | 4/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Krishna Institute of Medical Sciences or Neuland Laboratories?
Krishna Institute of Medical Sciences has a market cap of ₹30,366 Cr and Neuland Laboratories has a market cap of ₹25,414 Cr as of 06 Nov 2026.
Which has a lower P/E, Krishna Institute of Medical Sciences or Neuland Laboratories?
Neuland Laboratories has the lower P/E: Krishna Institute of Medical Sciences trades at 143.0 and Neuland Laboratories at 56.2.
Which gave better returns in the last year, Krishna Institute of Medical Sciences or Neuland Laboratories?
Neuland Laboratories did better: Krishna Institute of Medical Sciences returned -1.7% and Neuland Laboratories returned +27.9% over one year.
Is Krishna Institute of Medical Sciences or Neuland Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Krishna Institute of Medical Sciences scores 4/10 and Neuland Laboratories scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.